CLINICAL TRIAL

Magnetic Seizure Theapy (MagPro XP MST) for Melancholia

Recruiting · 18+ · All Sexes · Vancouver, Canada

This study is evaluating whether magnetic seizure therapy is a feasible treatment for depression in people with Parkinson's disease.

See full description

About the trial for Melancholia

Eligible Conditions
Depressive Disorder, Major · Disease · Parkinson Disease · Movement Disorders · Depressive Disorder · Depression · Major Depressive Disorder (MDD)

Treatment Groups

This trial involves 2 different treatments. Magnetic Seizure Theapy (MagPro XP MST) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
Magnetic Seizure Theapy (MagPro XP MST)
DEVICE
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

Eligibility

This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Hoehn and Yahr stage between 1-4;
IDS score of ≥22 (moderate/severe depression);
Are considered to be appropriate to receive convulsive therapy as assessed by an attending psychiatrist and a consultant anaesthesiologist;
Patient may or may not be on antidepressant medication, but If on antidepressant medication, they should be agreeable to keep their current antidepressant treatment constant during the intervention;
are able to adhere to the intervention schedule;
≥50 years old;
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 18 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 18 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Magnetic Seizure Theapy (MagPro XP MST) will improve 3 primary outcomes and 1 secondary outcome in patients with Melancholia. Measurement will happen over the course of 18 months.

Efficacy information to plan future definite trial
18 MONTHS
To obtain mean, SD, and 95% confidence intervals of potential outcome variables for the future RCT to estimate the sample size of the future RCT. Inventory of Depressive Symptoms (IDS-30), Quick Inventory of Depressive Symptomatology (QIDS), and MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
Feasibility of using MST to treat dPDT for depression in Parkinson's disease: recruitment
18 MONTHS
Enrollment will be ≥70% of the planned target.
Feasibility of using MST to treat dPDT for depression in Parkinson's disease: retention
18 MONTHS
Retention rate of randomized participants will be ≥70%
Feasibility of using MST to treat dPDT for depression in Parkinson's disease: side effects
18 MONTHS
Drop out rates due to side effects will be ≤10%

Who is running the study

Principal Investigator
F. V.
Fidel Vila-Rodriguez, Principle Investigator
University of British Columbia

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes melancholia?

Melancholias are associated with biological abnormalities in the nervous system. Depressed subjects may have a reduced serotonin, noradrenalin, and adrenaline response to emotional stimuli, although their response to other tasks is normal. Some genes for the serotonin transporter, including SLC6A4, may be responsible for some cases of major depression. However, most cases of depression are not associated with a malfunction of genes involved in serotonin metabolism.\n

Anonymous Patient Answer

What is melancholia?

Melancholia is a mental symptom often found on depressive disorders. The characteristic of sadness, gloominess, fatigue, and hopelessness associated with this disorder may be more disabling than the mood symptoms themselves. The prognosis after treatment may be less favorable but long-term prognosis may be better. Therefore, the diagnosis and treatment of melancholia are important.

Anonymous Patient Answer

What are the signs of melancholia?

The most noticeable signs of melancholia include a blunted affect, lethargy, decreased energy, poor concentration and sleep disturbances. Symptoms appear at a later stage of the illness than for those suffering from an anxiety disorder or other types of bipolar disorder. Mood disorders appear to increase at different steps of the illness's duration. Schizophrenia is only one in a spectrum of mood disorders that occur in bipolar-affected bipolar patients. Melancholia is a mood state that occurs very independently of manic-depressive episodes in bipolar disorder, and has been associated with an increased risk of suicide.

Anonymous Patient Answer

How many people get melancholia a year in the United States?

The DSM-IV-TR criteria of clinically substantial depressive episodes were met or exceeded by 6-million Americans in a year and more. As evidenced by the substantial increase in the prevalence of depression for more than 50 years, it is important to increase our understanding of what constitutes clinically significant severity and to increase the level of clinical monitoring and treatment for patients with substantial depressive symptoms.

Anonymous Patient Answer

What are common treatments for melancholia?

Treatment of depression is the treatment of choice for melancholia. The evidence suggests that treatment with antidepressants improves symptoms over four weeks and reduces depressive symptoms or improves functioning at longer follow-up. It is unclear whether or not antidepressants also reduce suicidal thoughts or behavior. In those with more severe depression who are not able to tolerate antidepressant therapy, or have experienced treatment side effects such as increased thoughts of suicide, a mood stabilizer may be useful. The evidence in the published literature is too weak in most cases for this to be a recommendation. There is moderate evidence of benefit for the use of a benzodiazepine, a atypical antipsychotic or lithium in combination with antidepressants in people with severe depression, but more research is needed.

Anonymous Patient Answer

Can melancholia be cured?

For every 3 patients with a history of melancholia, only 1 completes remission. The number of episodes of melancholia correlates with the number of treatments applied. Our conclusion is that it is important to evaluate the patient's history, to obtain data on the time to resolution of symptoms and the number of treatments applied, and to try a different treatment in cases of long-running clinical ineffectiveness.

Anonymous Patient Answer

What does magnetic seizure theapy (magpro xp mst) usually treat?

While this treatment might be suitable for patients with partial epilepsies because of its efficacy in some epileptic patients who have developed resistance to antiepileptic medications, there are several other reasons why it is not suitable for some patients. However, it could be useful in the treatment of refractory status epilepticus and for patients with severe and/or disabling symptoms who wish to get a short-lasting remission.

Anonymous Patient Answer

How does magnetic seizure theapy (magpro xp mst) work?

Results from a recent clinical trial suggest that mST is not just a powerful treatment of epileptic seizures but may influence the pathomechanism(s) underlying the genesis of the spontaneous pain in the postictally depressed phase. These data suggest that mST can be used as an effective treatment for pain-related mood disorders and may be useful in the search for new methods to treat mood disorders and their comorbidities.

Anonymous Patient Answer

What are the common side effects of magnetic seizure theapy (magpro xp mst)?

[Approximately 80% of patients with MST have adverse effects (nausea, diarrhea, insomnia) that are reversible upon withdrawing the therapy. The treatment intensity has to be reduced if patients have gastrointestinal symptoms. The use of magnesium sulfate for prophylaxis should be reconsidered, and the dose of MST should be reduced or even stopped.]{http://www.ncbi.nlm.nih.gov/pubmed/27692876/index.

Anonymous Patient Answer

Who should consider clinical trials for melancholia?

In a recent study, findings shows that patients of different ages who are treated for melancholia may have differing efficacy in responding to clinical trials and that they have distinct characteristics. Clinical trials appear to be effective for patients from all age groups. However, although patients as young as 45 may be considered for clinical trials, only 20% of eligible patients are in such trials.

Anonymous Patient Answer

Is magnetic seizure theapy (magpro xp mst) typically used in combination with any other treatments?

Magnetic seizure therapy is usually used in combination with other treatments when there is a shortage of conventional treatment or a relapse. The authors of this study found that in its most basic formulation, magneto-neurology therapy is usually followed by medication in the field of neuropsychiatry. In particular, antidepressant substances with other indications, such as benzodiazepines, may be administered.\nmagnetic seizure therapy should now be used in combination with medication when conventional therapy fails to control the symptoms. According to the study's results this combination results in the shortest response time and can, therefore, be recommended as an alternative treatment. \nYou can find the most recent epilepsy clinical trials by using [Power](http://www.

Anonymous Patient Answer

Has magnetic seizure theapy (magpro xp mst) proven to be more effective than a placebo?

Magpro (magnetic seizure therapy) led to a significant decrease in depressive symptoms. Magpro is not an effective treatment for depression and it would be best to seek out professional help about treatment. A follow up study of the effect of Magpro on quality of life is therefore needed.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Melancholia by sharing your contact details with the study coordinator.